Compare · ABUS vs ROIV
ABUS vs ROIV
Side-by-side comparison of Arbutus Biopharma Corporation (ABUS) and Roivant Sciences Ltd. (ROIV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABUS and ROIV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ROIV is the larger of the two at $26.10B, about 27.0x ABUS ($965.5M).
- ROIV has been more active in the news (28 items in the past 4 weeks vs 5 for ABUS).
- ROIV has more recent analyst coverage (19 ratings vs 3 for ABUS).
- Company
- Arbutus Biopharma Corporation
- Roivant Sciences Ltd.
- Price
- -
- -
- Market cap
- $965.5M
- $26.10B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 5
- 28
- Recent ratings
- 3
- 19
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical trial collaboration agreement with Vaccitech plc to evaluate a therapeutic combination for the treatment of subjects with chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest ABUS
- President and CEO Androski Lindsay exercised 126,864 shares at a strike of $3.30 and covered exercise/tax liability with 82,527 shares, increasing direct ownership by 158% to 72,337 units (SEC Form 4)
- Chief Financial Officer Nguyen Tuan exercised 293,100 shares at a strike of $3.57 and covered exercise/tax liability with 206,637 shares, increasing direct ownership by 118% to 159,963 units (SEC Form 4)
- Director Sawhney Roger exercised 131,333 shares at a strike of $3.88 and covered exercise/tax liability with 100,508 shares (SEC Form 4)
- Director Beardsley Robert A exercised 131,333 shares at a strike of $3.82 and covered exercise/tax liability with 99,057 shares (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Arbutus Biopharma Corporation
- SEC Form SC TO-I filed by Arbutus Biopharma Corporation
- Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
- SEC Form SC TO-C filed by Arbutus Biopharma Corporation
- Arbutus Biopharma Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
Latest ROIV
- Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
- Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
- Chief Accounting Officer Humes Jennifer covered exercise/tax liability with 3,880 shares, decreasing direct ownership by 4% to 106,419 units (SEC Form 4) (for tax liability)
- CFO Pulik Richard covered exercise/tax liability with 2,129 shares, decreasing direct ownership by 0.78% to 269,681 units (SEC Form 4) (withholding tax)
- Director Manchester Keith S was granted 5,054 shares, increasing direct ownership by 0.29% to 1,753,457 units (SEC Form 4)
- Director Gold Daniel Allen was granted 5,054 shares, increasing direct ownership by 0.06% to 8,965,815 units (SEC Form 4)
- Director Oren Ilan was granted 5,054 shares, increasing direct ownership by 4% to 123,680 units (SEC Form 4)
- Director Momtazee James C was granted 5,054 shares, increasing direct ownership by 5% to 111,959 units (SEC Form 4)
- Director Fitzgerald Meghan was granted 5,054 shares, increasing direct ownership by 14% to 41,162 units (SEC Form 4)
- Director Epperly Melissa B, was granted 5,054 shares, increasing direct ownership by 51% to 14,954 units (SEC Form 4)